This post now available at the Health Affairs Blog by Tricia Neuman, Jack Hoadley, and Juliette Cubanski discusses Sovaldi (sofosbuvir), an oral drug recently approved by the FDA for the treatment of chronic hepatitis C, and the potential impact of this long-awaited cure on Medicare spending and Part D premiums.  It is authored by the Foundation’s Tricia Neuman, Jack Hoadley of Georgetown University’s Health Policy Institute, and the Foundation’s Juliette Cubanski.